{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T17:23:09.755685",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 143,
    "source_countries": [
      "AT",
      "BE",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "mortality",
        "disease-free survival",
        "recurrence-free survival",
        "life expectancy",
        "five-year survival",
        "one-year survival",
        "annual mortality",
        "survival calculated from the date of diagnosis",
        "long-term survival",
        "survival after transplantation",
        "survival after surgical resection",
        "survival after percutaneous local ablative therapy",
        "survival after transarterial chemoembolization",
        "survival after radioembolization",
        "survival after systemic therapy",
        "survival after best supportive therapy",
        "survival after combined locoregional therapies",
        "survival after antiviral therapy",
        "survival after adjuvant therapy",
        "survival after neoadjuvant therapy",
        "survival after down-staging",
        "survival after portal thrombectomy",
        "survival after hepatic resection with portal thrombectomy",
        "survival after supportive therapy",
        "survival after tamoxifen therapy",
        "survival after antiandrogen therapy",
        "survival after chemotherapy",
        "survival after doxorubicin therapy",
        "survival after FOLFOX4 therapy",
        "survival after TACE with drug-eluting beads",
        "survival after TACE alone",
        "survival after radiofrequency ablation",
        "survival after partial hepatectomy",
        "survival after percutaneous alcohol injection",
        "survival after acetic acid injection",
        "survival after transplantation outside Milan criteria",
        "survival after transplantation within Milan criteria"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1, mRECIST, or as specified)",
        "complete response (CR)",
        "partial response (PR)",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD; for at least 16 weeks or as specified)",
        "disease control rate (DCR; RECIST or mRECIST, as specified)",
        "clinical benefit rate (CBR)",
        "tumor response rate",
        "radiologic response",
        "pathological response",
        "tumour response to locoregional therapy",
        "tumour necrosis",
        "tumour necrosis volume",
        "tumor reduction",
        "local control",
        "local control rates",
        "local recurrence",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (modified RECIST criteria)",
        "response rates (multiphase computed tomography or magnetic resonance imaging with contrast)",
        "radiological assessment of response (DT or MRI with intravenous multiphase contrast)",
        "radiological assessment of viable tumor (mRECIST)",
        "radiological assessment of viable tumor (LR-TR viable, LR-TR equivocal, LR-TR nonviable)",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "tumour suppression",
        "tumour downstaging",
        "improved tumour response",
        "bridge to transplant",
        "bridging to transplantation"
      ],
      "progression_measures": [
        "progression-free survival (PFS; RECIST 1.1 or as specified)",
        "time to progression (TTP)",
        "time to radiological disease progression",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to disease progression",
        "disease progression",
        "time to tumour progression",
        "time to progression of the tumor",
        "reduction of progression",
        "recurrence rate",
        "recurrence",
        "risk of recurrence",
        "risk factors for recurrence (tumour size > 5cm, multiple tumours in the liver, vascular invasion, low differentiation)",
        "tumour recurrence",
        "time to tumour recurrence",
        "local recurrence",
        "drop-out rate",
        "duration of response (DoR)",
        "time to response",
        "duration of treatment (TTD)",
        "treatment duration",
        "time from randomisation or initiation of treatment to the occurrence of progression or death (progression-free survival, minimum follow-up of 1 year)"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded according to the National Cancer Institute)",
        "adverse events (CTCAE v5.0)",
        "adverse events (perioperative)",
        "adverse events (radioembolization)",
        "adverse events (chemoembolization)",
        "adverse events (thermoablation)",
        "adverse events (liver resection)",
        "adverse events (liver transplantation)",
        "adverse events (systemic therapy)",
        "serious adverse events (SAEs)",
        "serious adverse reactions",
        "major adverse events",
        "major complications",
        "complication incidence",
        "complications",
        "serious complications",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "grade 3 or higher adverse reactions",
        "treatment-related deaths",
        "treatment-related mortality",
        "dropout rate for critical toxicity",
        "adverse reactions leading to discontinuation of treatment",
        "adverse events leading to discontinuation",
        "post-treatment complications",
        "post-TACE syndromes",
        "post-TACE syndromes (pain, fever, nausea, vomiting)",
        "post operative liver failure",
        "perioperative mortality",
        "morbidity",
        "limited toxicity",
        "low risk and limited side effects",
        "complication rate",
        "intraoperative complications",
        "hand-foot syndrome",
        "hand-foot skin reaction",
        "hand-foot skin reaction (grade 3 or 4)",
        "hand feeding reactions (grade 3/4)",
        "dermatological toxicities",
        "skin rash",
        "rash",
        "palmar rash",
        "rash or skin desquamation (grade 3 or 4)",
        "desquamation",
        "skin desquamation",
        "dry skin",
        "erythema",
        "pruritus",
        "itching",
        "alopecia",
        "acne",
        "dermatitis exfoliative",
        "hyperkeratosis",
        "myalgia",
        "muscle spasms",
        "arthralgia",
        "fatigue",
        "asthenia",
        "pain",
        "abdominal pain",
        "joint pain",
        "back pain",
        "headache",
        "fever",
        "fever without cause",
        "influenza like illness",
        "nausea",
        "vomiting",
        "diarrhoea",
        "diarrhea",
        "constipation",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "mucosal inflammation",
        "gastro-oesophageal reflux disease",
        "intestinal failure",
        "gastrointestinal disorders",
        "gastrointestinal perforation",
        "gastrointestinal perforations",
        "gastrointestinal fistulas",
        "non-gastrointestinal fistulas",
        "bleeding",
        "haemorrhage",
        "brain haemorrhage",
        "brain/gastrointestinal bleeding",
        "haemorrhagic events",
        "gastrointestinal bleeding",
        "risk of bleeding",
        "risk of seeding",
        "tumour seeding",
        "infections",
        "sepsis",
        "liver failure",
        "hepatic failure",
        "irreversible liver failure",
        "liver disorders",
        "hepatic impairment",
        "hepatic encephalopathy",
        "encephalopathies",
        "hepatic insufficiency",
        "synthetic liver function",
        "liver injury",
        "biliary injury",
        "portal vein thrombosis",
        "portal hypertension",
        "bleeding risk from varicose veins",
        "changes in portal pressure",
        "ascites",
        "renal events",
        "renal failure",
        "proteinuria",
        "increased serum bilirubin",
        "increased bilirubin",
        "increased ALT activity (grade 3 or 4)",
        "increased alanine aminotransferase (ALT)",
        "increased aspartate aminotransferase (AST)",
        "transient increase in transaminases",
        "increased amylase",
        "increased lipase",
        "QTc interval prolongation",
        "QTc prolongation",
        "cardiac ischaemia",
        "myocardial ischaemia",
        "cardiac infarction",
        "myocardial infarction",
        "cardiac insufficiency",
        "congestive heart failure",
        "cardiovascular arrest",
        "arterial hypertension",
        "hypertension",
        "hypertension (grade 3/4)",
        "arterial thromboembolic events",
        "thromboembolic events",
        "venous thromboembolic events",
        "cerebral vascular accident",
        "sudden death",
        "wound healing complications",
        "lymphoedema (grade 3/4)",
        "lymphopenia",
        "leukopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "minor response (reduction of tumour size by 25 to 50%)",
        "myelosuppression",
        "hypothyroidism",
        "hyperthyroidism",
        "immuno-mediated hepatitis",
        "hepatic insufficiency",
        "hepatic encephalopathy",
        "encephalopathies",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hypophosphataemia",
        "decreased appetite",
        "loss of appetite",
        "anorexia",
        "weight loss",
        "weight loss (grade 3 or 4)",
        "decreased weight",
        "diabetes mellitus",
        "epilepsy",
        "depression",
        "anxiety",
        "stress",
        "peripheral sensory neuropathy",
        "dysgeusia",
        "tinnitus",
        "flushing",
        "rhinorrhoea",
        "dysphonia",
        "infusion reactions",
        "erythema",
        "folliculitis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "tumour necrosis",
        "tumour necrosis volume",
        "postoperative softening",
        "gallbladder abscess",
        "portal vein thrombosis",
        "hepatic arterial thrombosis",
        "biliary injury",
        "erectile dysfunction",
        "hand-foot skin reaction (grade 3 or 4)",
        "rash or skin desquamation (grade 3 or 4)",
        "serious adverse events",
        "serious adverse reactions",
        "major adverse events",
        "major complications"
      ],
      "serious_events": [
        "serious adverse events (SAEs)",
        "serious adverse reactions",
        "major adverse events",
        "major complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "perioperative mortality",
        "sudden death"
      ],
      "discontinuations": [
        "adverse reactions leading to discontinuation of treatment",
        "adverse events leading to discontinuation",
        "drop-out rate",
        "dropout rate for critical toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D visual analogue scale (VAS)",
        "EQ-5D health utility index (HUI)",
        "EQ VAS (Euro QoL visual analogue scale)",
        "SF-36",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep (Functional Assessment of Cancer Therapy – Hepatobiliary)",
        "FHSI-8 questionnaire",
        "Karnofsky index",
        "NRS Symptomatic Rating Scale (Symptomatic Validation Instrument)",
        "Numeric Rating Scale (NRS) 0-10",
        "visual analogue scale",
        "overall QoL measured with a validated and reliable instrument"
      ],
      "functional_status": [
        "cognitive functioning (health-related quality of life dimension)",
        "body image (EORTC QLQ-HCC18 functional scale)",
        "nutrition (EORTC QLQ-HCC18 functional scale)",
        "sex life (EORTC QLQ-HCC18 functional scale)",
        "role functioning (EORTC QLQ-C30 functional scale)",
        "fitness subscale (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-HCC18)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale)"
      ],
      "symptom_measures": [
        "symptoms (EORTC QLQ-C30 symptom scales)",
        "pain (EORTC QLQ-C30 domain)",
        "diarrhoea (EORTC QLQ-C30 domain)",
        "nutrition (EORTC QLQ-HCC18 domain)",
        "body image (EORTC QLQ-HCC18 domain)",
        "distress (physical and psychological complaints)",
        "degree of persistence of symptoms",
        "time to deterioration (EORTC QLQ-C30 and EORTC QLQ-HCC18; defined as a score increase by at least 10 points over baseline)",
        "time-to-symptom worsening (TSW; EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D VAS, EQ-5D HUI)",
        "deterioration in patient quality of life (based on EORTC QLQ-C30)",
        "deterioration in patient quality of life (based on EORTC QLQ-HCC18)",
        "health status",
        "quality of life",
        "health-related quality of life",
        "overall QoL measured with a validated and reliable instrument"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness analysis",
        "cost-benefit analysis",
        "cost comparison",
        "cost minimisation analysis",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)",
        "economic outcomes (cost-effectiveness, incremental cost-effectiveness ratio, ICER)",
        "economic outcomes (quality-adjusted life years, cost-effectiveness, incremental cost-effectiveness ratio, ICER)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)"
      ],
      "resource_utilization": [
        "length of hospital stay (LOS)",
        "length of hospital stay",
        "length of admission",
        "days of missed work",
        "need for hospital medical day (HDM)",
        "intrahospital administration",
        "outpatient regimen",
        "ambulatory regimen",
        "resource use"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "prognosis (BCLC staging system)",
        "therapeutic efficacy",
        "recurrence detection",
        "recurrence rate after transplantation",
        "diagnostic accuracy",
        "effect of ablative or neoadjuvant therapy (estimated percentage of vital tumour tissue)",
        "hypertrophy of untreated liver",
        "downstaging to achieve resectability or Milan criteria for transplantation",
        "tumour response to locoregional therapy",
        "tumour necrosis volume",
        "tumour necrosis",
        "tumour suppression",
        "tumour downstaging",
        "bridge to transplant",
        "bridging to transplantation",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "AFP monitoring",
        "detection of early hepatocellular carcinoma",
        "recurrence detection",
        "recurrence rate after transplantation",
        "response rates (multiphase computed tomography or magnetic resonance imaging with contrast)",
        "local tumor control",
        "local tumour control",
        "local control rates"
      ],
      "biomarkers": [
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "vital signs",
        "pharmacokinetics (PK)",
        "plasma pharmacokinetics exposure parameters",
        "PK/PD relationship between exposure and efficacy/safety",
        "pharmacokinetic parameters",
        "radiological assessment of response (DT or MRI with intravenous multiphase contrast)",
        "radiological assessment of viable tumor (mRECIST)",
        "radiological assessment of viable tumor (LR-TR viable, LR-TR equivocal, LR-TR nonviable)"
      ]
    }
  }
}